VERU INC. - COMMON STOCK

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

05 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

21 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

16 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Present at the 2024 Cantor Global Healthcare Conference

11 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

08 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

01 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Participate in the BTIG Virtual Biotechnology Conference

29 Jul 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

02 Jul 2024 08:30:00 By Nasdaq GlobeNewswire

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

24 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

18 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders

17 Jun 2024 16:45:00 By Nasdaq GlobeNewswire

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

10 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Present at the Jefferies Global Healthcare Conference

22 May 2024 08:30:00 By Nasdaq GlobeNewswire

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

15 May 2024 08:30:00 By Nasdaq GlobeNewswire

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

14 May 2024 08:30:00 By Nasdaq GlobeNewswire

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

08 May 2024 06:30:00 By Nasdaq GlobeNewswire

Veru to Present at the GLP-1 Based Therapeutics Summit

02 May 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

01 May 2024 08:30:37 By Nasdaq GlobeNewswire

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

30 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

25 Apr 2024 08:30:00 By Nasdaq GlobeNewswire